Clinical research in cardiology : official journal of the German Cardiac Society
-
Review Meta Analysis
Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.
Standard inotropic treatment is often necessary in end-stage heart failure but may be harmful. We performed a meta-analysis of randomized controlled trials to investigate the effect of repeated administration of levosimendan on survival in patients with chronic heart failure. ⋯ A large randomized trial is necessary to confirm the promising beneficial effects of intermittent levosimendan administration on the mid-term survival of patients with chronic heart failure.